Epinephrine personal autoinjectors cost-effective at $24

(HealthDay)—In a simulation of children with peanut allergy, epinephrine personal autoinjectors are cost-effective at $24, according to a study published online Nov. 16 in JAMA Network Open. Marcus Shaker, M.D., from the Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire, and Matthew Greenhawt, M.D., from the University of Colorado School of Medicine in Aurora, assessed cost ceilings for value-based epinephrine prices […]

Read more

Clementia Announces Plan to Submit a New Drug Application for Palovarotene for the Treatment of FOP Based on Positive Phase 2 Results

MONTREAL, Oct. 23, 2018 (GLOBE NEWSWIRE) — Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced that it plans to submit a New Drug Application (NDA) for palovarotene to the U.S. Food and Drug Administration (FDA) in the second half of 2019. Based on recent interactions between […]

Read more

US health chief says overdose deaths beginning to level off

The number of U.S. drug overdose deaths has begun to level off after years of relentless increases driven by the opioid epidemic, health secretary Alex Azar said Tuesday, cautioning it’s too soon to declare victory. “We are so far from the end of the epidemic, but we are perhaps, at the end of the beginning,” Azar said in prepared remarks […]

Read more

FDA Approves Dupixent (dupilumab) for Moderate-to-Severe Asthma

PARIS and TARRYTOWN, N.Y., Oct. 19, 2018 /PRNewswire/ — Sanofi (EURONEXT: SAN) (NYSE: SNY) The U.S. Food and Drug Administration has approved Dupixent® (dupilumab) as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma. Dupixent inhibits the overactive signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13), two […]

Read more

Common use of antipsychotics shown ineffective for delirium in intensive care patients

Critically ill patients in intensive care units (ICUs) did not benefit from two antipsychotic drugs used to treat delirium, according to a large clinical trial funded by the National Institute on Aging, part of the National Institutes of Health. The multi-site team that conducted the trial found no evidence that treatment with antipsychotic medicines—haloperidol or ziprasidone—affected delirium, survival, length of […]

Read more

Prescription opioid and benzodiazepine misuse linked with suicidal thoughts

Misuse of prescription opioids or benzodiazepines (such as Xanax) was associated with suicidal ideation in a study of US older adults. In the International Journal of Geriatric Psychiatry study of 17,608 adults aged 50 years and older, past-year use (without misuse) of prescription opioids or benzodiazepines was not associated with past-year suicidal ideation. In contrast, past-year opioid misuse was associated […]

Read more

Research assesses geographic distribution of new antibiotics following market introduction

There is a growing need for new antibiotics to help combat the looming threat of antimicrobial resistance. According to a new study conducted by researchers at the Center for Disease Dynamics, Economics & Policy (CDDEP) with colleagues at the University of Oslo, and other organizations, between 1999 and 2014, only 25 new antibiotics representing nine different antibiotic classes entered the […]

Read more

Despite crisis patients perceive opioids as superior and expect them for postsurgical pain

Even with concerns about addiction, side effects and the other risks of opioids dominating headlines, a study presented at the ANESTHESIOLOGY 2018 annual meeting found people expect to be prescribed opioids and perceive them to be the most effective form of pain relief after surgery. Interestingly, other research presented at the meeting found opioids led to complications such as increased […]

Read more

Oryzon Announces First Patient Enrolled in REIMAGINE: a Phase IIa Clinical Trial with Vafidemstat (ORY-2001) in Aggressiveness

MADRID, Spain and CAMBRIDGE, Mass., Oct. 09, 2018 (GLOBE NEWSWIRE) — Oryzon Genomics S.A. (ISIN Code: ES0167733015, ORY), (“Oryzon”), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, has announced today that the first patient has been enrolled in the REIMAGINE Phase IIa trial with Vafidemstat (ORY-2001) in patients with episodes of […]

Read more
1 … 17 18 19 20 21 … 24